

A Overview Of Type And New Emerging Preventive Measures Of Mammary Carcinoma

Anusha Jasmin R J¹, Ramalingam Kothai^{*2}, Balasubramanian Arul³

¹Research Scholar, Vinayaka Mission's Research Foundation, Salem.

^{2,3} Professor, Department of Pharmacology, Vinayaka Mission's College of Pharmacy, Vinayaka Mission's Research Foundation (Deemed to be University), Salem-636008, Tamilnadu, India

*Corresponding Author E-mail: kothair@vmpha.co.in

ABSTRACT

The illness known as breast cancer is caused by aberrant breast cells that proliferate and develop into tumors. Worldwide, breast cancer affects people in every nation. Globally, breast cancer claimed 670 000 lives. Women without any particular risk factors other than age and sex account for almost half of all cases of breast cancer. In 157 nations, breast cancer was the most frequent cancer among women. Men are affected by breast cancer in a range of 0.5–1%. Tumours have the potential to grow throughout the body and become lethal if ignored. Inside the breast's milk ducts or milk-producing lobules are where breast cancer cells first proliferate. The earliest form is detectable in its early stages and is not life-threatening. Nearby breast tissue can become infected with cancerous cells. Tumors produced by this result in thickening or lumps. Cancers that are invasive can spread to adjacent lymph nodes or other organs. Metastasis can be lethal and perhaps fatal. Treatment is determined by the patient and the cancer's type, and its extent of dissemination. Medication, radiation therapy, and surgery are all used in treatment and life style change to reduce the risk of mammary carcinoma.

KEY WORDS: life-threatening, tumours, lumps, milk-producing lobules, Metastasis

INTRODUCTION

These days, the most common cancer in women is breast cancer. The strongest risk factor for breast cancer is female gender. Women get breast cancer in about 99% of cases, while men get breast cancer in 0.5–1% of cases. The care of breast cancer in men is based on the same concepts as in women. Ageing, obesity, heavy alcohol use, radiation exposure history, family history of breast cancer, reproductive history, tobacco use, and postmenopausal hormone therapy are some of the factors that raise the risk of breast cancer. Other than age (over 40) and gender (female) women without any other known breast cancer risk factor account for around half of all cases of breast cancer.

RISK FACTOR

The risk of breast cancer is increased by a family history of the disease. A woman's risk does not always decrease if her family history is unknown. Breast cancer risk is significantly increased by some gene alterations. Most breast cancers have an unknown specific cause. Some factors have been identified by researchers as raising the risk of breast cancer. These consist of environmental factors, lifestyle decisions and hormones².

SIGNS AND SYMPTOMS

Early cancer identification is crucial because the majority of people do not exhibit any symptoms when the disease is still in its early stages. Breast cancer symptoms can include thickening or lumps and frequently without any pain. Alteration in the breasts' size, shape, or appearance skin changes such as dimpling, redness, pitting, or others. Alteration in the look of the nipple or the skin (areola) surrounding it, as well as unusual or bloody nipple fluid a thicker patch of skin or breast lump that feels unnatural in relation to the surrounding tissue. A nipple that curves inward or appears flattened and variations in the skin tone of the breasts. White skinned individuals may have pink or red breast skin. Individuals with brown or black skin types may have darker breast skin compared to the rest of their chest, or their breast skin may seem reddish-purple. Alteration to a breast's size, form, or appearance. alterations to the skin over the breast, such as orange peel-like or dimpled skin and flaking, peeling, scaling, or crusting of the breast skin⁶.

Not all breast lumps are cancerous. When malignant breast tumors are tiny and have not migrated to neighboring lymph nodes, they have a better chance of being effectively treated. Breast cancers have the potential to spread to other body parts and cause additional symptoms. Cancerous cells have the ability to spread to other organs such as the brain, liver, lungs, and bones over time. Once they get at these locations, further cancer-related symptoms including headaches or bone pain could manifest. The cancer cells may aggregate into a mass known as a tumor. The tumor has the potential to

spread and engulf healthy bodily tissue. Cancer cells have the ability to split out and travel to other areas of the body over time. Metastatic cancer is the term for cancer that spreads. The cells lining the milk ducts are typically where the DNA alterations that cause breast cancer occur. The tubes in these ducts are meant to transport milk to the nipple. Invasive ductal carcinoma is the name given to breast cancer that begins in the ducts. Cells in the milk glands may also serve as the source of breast cancer. The purpose of these glands, known as lobules, is to produce breast milk. Invasive Lobular carcinoma is the name for cancer that develops in the lobules¹⁰.

CAUSES OF MAMMARY CANCER

The following are some factors that may raise the risk of breast cancer:

Breast cancer in one's family risk, developing breast cancer is raised if a parent, sibling, or child has the disease. Additionally having several family members who have breast cancer increases your risk. Nevertheless the majority of patients with breast cancer do not have a family history of the condition. Personal experience with breast cancer are more likely to develop cancer in the other breast if you have already had cancer in the first and a personal background of breast diseases⁹.

A increased risk of breast cancer is indicated by certain breast diseases. These ailments include atypical hyperplasia of the breast and lobular carcinoma in situ or LCIS. The persons are more likely to develop breast cancer if a breast biopsy revealed one of these disorders starting your menstrual cycle earlier in life. Breast cancer risk increases if you start your period before the age of twelve and starting the menopause later in life. Breast cancer risk increases at the age of 55 when menopause starts being a woman¹⁶. Breast cancer is far more common in women than in men. Since breast tissue is present in all people from birth and anyone can develop breast cancer for breast tissue that is dense. Dense tissue and fatty tissue make up breast tissue. Fibrous tissue, milk ducts, and milk glands make up dense tissue. More dense tissue than fatty tissue makes up a person with dense breasts. Breast density can affect the mammography's ability to identify breast cancer. Womens have a higher chance of developing breast cancer if a mammography revealed that your breasts are thick. Discuss any further tests you may have in addition to mammograms to check for breast cancer with your healthcare provider¹¹. Breast cancer risk is increased by alcohol consumption.

Breast cancer risk is decreased with one or more pregnancies. As you age and your chance of breast cancer increases by inherited mutations in DNA that raise the chance of cancer. Certain genetic alterations can be inherited by offspring and raise the risk of breast cancer. The most famous alterations are referred to as BRCA1 and BRCA2. Although not everyone with these DNA alterations develops cancer, they can significantly raise your risk of breast cancer and other malignancies⁹.

Treatment for menopause hormones, Breast cancer risk may rise if certain hormone treatment medications are taken to manage menopausal symptoms¹⁴. Hormone therapy medications that mix progesterone and estrogen are associated with a risk. When you stop using these medications the risk decreases. Being overweight the individuals who are obese are more likely to develop breast cancer and exposure to radiation. Your risk of breast cancer is increased if you had radiation treatments to your chest as a young adult or child¹⁵.

TYPES OF BREAST CANCER

Breast cancer comes in a variety of forms, each with its own nomenclature.

The particular cells in the breast that develop into cancer dictate the type of breast cancer. The majority of breast cancers are carcinomas or tumors that begin in the epithelial cells lining the organs and tissues throughout the body. Lobular or ductal carcinomas are among these types of cancers. Adenocarcinomas, which originate in cells in the ducts (the milk ducts) or the lobules (the milk-producing glands in the breast), are typically the more specific type of carcinomas that arise in the breast. Whether or not the cancer has spread might also be indicated by the type of breast cancer³.

A pre-cancerous condition known as in situ breast cancer (also known as ductal carcinoma in situ, or DCIS) begins in a milk duct and has not spread to the surrounding breast tissue. Any form of breast cancer that has extended (invaded) into the surrounding breast tissue is referred to as invasive breast cancer.

Intraductal carcinoma is another name for ductal carcinoma in situ (DCIS). This breast cancer is either pre-invasive or non-invasive. Breast tissue around the affected area has been affected by invasive (or infiltrating) breast cancer. Invasive ductal carcinoma and invasive lobular carcinoma are the most prevalent forms. Of all breast cancers, invasive ductal carcinoma accounts for 70–80% of cases. various varieties of invasive breast cancer. Certain invasive breast cancers have unique characteristics or develop in unique ways that affect how they are treated and how long they will last. While less frequent than other forms of breast cancer, these tumors have the potential to be more dangerous⁴.

Triple-negative breast cancer is an aggressive form of invasive breast cancer in which the cancer cells produce either too little or too much of the HER2 protein in addition to lacking ER or PR receptors⁹. (All three tests return "negative" results for the cells.) It makes up 15% of all cases of breast cancer and can be challenging to cure. An aggressive form of invasive breast cancer known as "inflammatory breast cancer" occurs when cancer cells obstruct epidermal lymph

veins, giving the appearance of a "inflamed" breast. It is extremely uncommon, making only 1% to 5% of all cases of breast cancer.

Breast cancer instances involving paget illness are extremely uncommon, making up only 1-3% of all occurrences. It begins in the breast ducts and progresses to the nipple's skin before reaching the areola, which is the black circle that encircles the nipple. Breast sarcomas are extremely uncommon, accounting for fewer than 1% of all breast cancer cases. Angiosarcoma originates from cells lining lymphatic or blood channels. It may affect the skin or the tissue of the breast. Some might be connected to radiation treatment in that region in the past and rare breast tumors are called phyllodes tumors. While carcinomas form in the ducts or lobules, they arise in the connective tissue (stroma) of the breast. While the majority are benign, some are malignant (cancer)⁷.

PREVENTIVE MEASURES

Best oneself examination, to reduce your risk of breast cancer by making lifestyle changes. Breast self-examination is a great way to raise awareness of your breasts. To do a breast self-exam for breast awareness and periodically examine your breasts to get to know them better. Report anything unusual or new to a healthcare provider if you notice any changes or lumps in your breasts²⁵. On most days of the week, work out. On most days of the week, try to get in at least 30 minutes of exercise. Breast cancer risk may increase with combination hormone therapy. Consult a medical expert about the advantages and disadvantages of hormone therapy. Menopause symptoms can be uncomfortable for certain people. Some may determine that in order to receive relief, the dangers associated with hormone therapy are tolerable. Use hormone therapy at the lowest possible dose for the shortest duration of time to lower the risk of breast cancer. Sustain a healthy weight. Try to keep your weight stable if it is healthy. Ask a medical practitioner about healthy strategies to reduce your weight if you need to lose weight. Reduce your calorie intake and gradually up your exercise regimen, drugs and procedures for people with a high risk of breast cancer, You may want to look at other options if your risk of breast cancer is high. If breast cancer runs in your family, you may be at a higher risk²⁶. Additionally, if you have a history of precancerous cells in your breast tissue, your risk may be increased. Those who are at a high risk of breast cancer can reduce their risk by using estrogen-blocking medications as preventive measures. Aromatase inhibitors and selective estrogen receptor modulators are among the available medications.

These medications are also used to treat breast cancer with hormone therapy. Side effects are a possibility with some medications. They are only used in people who have an extremely high chance of developing breast cancer because of this. Talk about the advantages and disadvantages with your medical staff.

Consider undergoing surgery as a preventive measure to reduce your chance of breast cancer. A preventive mastectomy, which involves removing the breasts, is one possible course of action. A preventive oophorectomy, or removal of the ovaries via surgery, is an additional alternative. The risk of ovarian and breast cancer is decreased by this procedure.

TREATMENT

Reduce the breast cancer risk

- Lifestyle changing – maintain healthy weight especially after menopause
- Eating healthy food – Eating fruits, vegetables, legumes, Exercise
- Breast feeding medication and reproductive history¹³
- Surgery like a prophylactic or risk reducing mastectomy can reduce the risk of cancer
- Other procedures like an oophorectomy or ovarian ablation can also reduce the risk of cancer.

The course of treatment for breast cancer is determined by the specific subtype of the disease and the extent to which it has spread to lymph nodes (stages I to III) or other regions of the body (stage IV). To reduce the likelihood of a cancer recurrence, doctors combine therapy. These consist of radiation therapy to lower the chance of recurrence in the breast and adjacent tissues, and surgery to remove the breast tumor.

- Drugs that destroy cancer cells and stop them from spreading, such as hormone treatments, chemotherapy, or biological therapies with specific targets. Early initiation and completion of treatment for breast cancer results in greater efficacy and higher tolerance.
- A lumpectomy, or removal of only the malignant tissue, or a mastectomy, involves removing the entire breast. To evaluate the cancer's potential for metastasis, lymph nodes may also be surgically removed.
- Radiation therapy reduces the likelihood of cancer returning on the chest wall and treats any microscopic malignancies that are still present in the breast tissue and/or lymph nodes²².

Advanced malignancies may not always hurt, but they can erode through the skin to leave open sores (ulceration). Women who have non-healing breast sores ought to consult a physician to have a biopsy done. The biological characteristics of breast cancer, as ascertained by specialized testing, are taken into consideration while choosing medications for treatment (tumour marker determination). The WHO Essential Medicines List (EML) already includes the vast majority of medications used to treat breast cancer. For aggressive tumors, lymph nodes are removed during cancer surgery. In the past, it was believed that total axillary dissection the removal of the entire lymph node bed beneath the arm was required to stop the spread of cancer. Sentinel node biopsy, a smaller lymph node technique, is now the recommended method due to its lower risk of complications⁹.

Based on the biological subtyping of the malignancies, medical treatments for breast cancers can be administered either before (known as "neoadjuvant") or after (known as "adjuvant") surgery. Triple negative breast cancer is a subtype in which the ER, PR, or HER-2 receptors are not expressed. It is one of the more aggressive forms of the disease. Endocrine (hormone) therapy, including tamoxifen or aromatase inhibitors, are likely to be effective in treating cancers that express the estrogen receptor (ER) and/or progesterone receptor (PR). These oral medications, which are administered for five to ten years, almost completely eliminate the risk of these "hormone-positive" malignancies returning¹⁴. Menopause symptoms may be brought on by endocrine treatments, although they are usually well tolerated. Chemotherapy is required for "hormone receptor negative" cancers, which do not express either the ER or the PR, unless they are very small. Today's chemotherapy regimens are typically administered as outpatient therapy and are very effective in lowering the risk of cancer spread or recurrence. When there are no side effects from chemotherapy for breast cancer, hospitalization is typically not necessary. Treatment options for HER-2 positive breast tumors include targeted biological medicines like trastuzumab. HER-2 positive breast cancers are those that independently overexpress the HER-2/neu oncogene. Chemotherapy is administered in conjunction with targeted biological therapies to maximize its ability to eradicate cancer cells²³.

CONCLUSION

Mammary Carcinoma is a malignancy for females, so many types are available there are Ductal or Lobular Carcinoma(Adenocarcinoma), Ductal carcinoma In Situ(Intra Ductal Carcinoma), Invasive Carcinoma(Infiltrating Carcinoma), Non Invasive Carcinoma(Pre Invasive carcinoma), Triple negative breast cancer, Inflammatory breast cancer, Paget disease of breast, Sarcomas of breast, Angiosarcoma, Phyllodes tumour. Out of this some of them are diagnosed by earlier. This malignancy was prevented by, Lifestyle changing – maintain healthy weight especially after menopause, Eating healthy food – Eating fruits, vegetables, legumes, Exercise, breast feeding medication, reproductive history, surgery like a prophylactic or risk reducing mastectomy can reduce the risk of cancer and other procedures like an oophorectomy or ovarian ablation.

REFERENCE

1. Charles V. Clevenger, Priacilla A. Furth, Susan E. Hankinson, Linda A. Schuler, The role of prolactin in mammary carcinoma. *Endocrine reviews* 2003; 24(1):1-27
2. Panal M.D, Lan, Macdonld, The natural history of mammary carcinoma. *Clin.Pathol.* 2018;71:52-58.
3. Andrea D. Abati M.D, Marek Kimmel, Paul P. Rosan M D. Apocrine mammary carcinoma: A clinicopathologic study of 72 cases. *American Journal of clinical Phathology*, 1990;94(4):371-377.
4. S Luna-More, B Gonzalez, C Acedo, I Rodrigo, Invasive micropillary carcinoma of the breast: a new special type of invasive mammary carcinoma, *Research and Practice*, 1994;190(7):668-674.
5. C Marques, J Correia, F Ferreira, A mammary carcinomas showed less aggressive clinicopathological features, contrasting with the cats that had triple negative carcinomas, 2016;8(8):1574 – 1575.
6. Elie Dagher, Jerome Abadie and Frederique, Feline Invasive Mammary Carcinomas: Prognostic Value of Histological Grading, 2019;56(5):7203.
7. Vuong D, Simpson PT, Green B, Cummings MC, Lakhani S R, Molecular classification of breast cancer. *Virchows Arch* 2014;465:1-14.
8. Rakha EA, Reis-Filho JS, Ellis IO, Combinatorial biomarker expression in breast cancer. *Breast Cancer Res Treat* 2010;120:293-308.
9. Lanari C, Lamb CA, Fabris VT, Helguero LA, Soldati R, Bottino MC et al, The MPA mouse breast cancer model:evidence for a role of progesterone receptors in breast cancer. *Endocr relat Cancer* 2009;16:333-350.
10. Dickson RB, Johnson MD, Bano M, Shi E, Kurebayashi J, Ziff B, Martinez-Lacaci I, Amundadottir LT, Lippman ME, Growth factors in breast cancer: mitogenesis to transformation. *J Steroid Biochem Mol Biol* 1992;43:69–78
11. Love R.R, Rose D.R, Surawicz T.S, Newcomb P.A, Prolactin and growth hormone levels in premenopausal women with breast cancer and healthy women with a strong family history of breast cancer. *Cancer* 1991; 68:1401–1405
12. Kwa H.G, Wang D.Y, An abnormal luteal-phase evening peak of plasma prolactin in women with a family history of breast cancer. *Int J Cancer* 1977; 20:12–14
13. Musey V.C, Collins D.C, Musey P.I, Martino-Saltzman D, Preedy J.R, Long-term effect of a first pregnancy on the secretion of prolactin. *N Engl J Med* 1987;316:229–234
14. Wang D.Y, De Stavola B.L, Bulbrook R.D, Allen D.S, Kwa H.G, Verstraeten A.A, Moore J.W, Fentiman I.S, Hayward J.L, Gravelle I.H, The permanent effect of reproductive events on blood prolactin levels and its relation to breast cancer risk: a population study of postmenopausal women. *Eur J Cancer Clin Oncol* 1988;24: 1225–1231
15. Ingram D.M, Nottage E.M, Roberts A.N, Prolactin and breast cancer risk. *Med J Aust.* 1990;153:469–473
16. Hankinson S.E, Colditz G.A, Hunter D.J, Manson J.E, Willett W.C, Stampfer M.J, Longcope C, Speizer FE, Reproductive factors and family history of breast cancer in relation to plasma estrogen and prolactin levels in postmenopausal women in the Nurses' Health Study (United States). *Cancer Causes Control* 1995; 6:217–224
17. Apter D, Reinila M, Vihko R, Some endocrine characteristics of early menarche, a risk factor for breast cancer, are preserved into adulthood. *Int J Cancer* 1989;44:783–787

18. Love R.R, Rose D.P, Elevated bioactive prolactin in women at risk for familial breast cancer. *Eur J Cancer Clin Oncol* 1985;21:1553–1554
19. Fishman J, Fukushima D, Connor J, Rosenfeld R.S, Lynch H.T, Lynch J.F, Guirgis H, Maloney K, Plasma hormone profiles of young women at risk for familial breast cancer. *Cancer Res* 1978; 38: 4006–4011
20. Pike M.C, Casagrande J.T, Brown J.B, Gerkins V, Henderson B.E, Comparison of urinary and plasma hormone levels in daughters of breast cancer patients and controls. *J Natl Cancer Inst* 1977;59: 1351–1355
21. Boffard K, Clark G.M, Irvine J.B, Knyba R.E, Bulbrook R.D, Wang D.Y, Kwa H.G, Serum prolactin, androgens, oestradiol and progesterone in adolescent girls with or without a family history of breast cancer. *Eur J Cancer Clin Oncol* 1981;17:1071–1077
22. Wolfe J.N. Risk for breast cancer development determined by mammographic parenchymal pattern. *Cancer* 1976;37:2486–2492
23. Byrne C, Schairer C, Wolfe J, Parekh N, Salane M, Brinton L.A, Hoover R, Haile R. Mammographic features and breast cancer risk: effects with time, age, and menopause status. *J Natl Cancer Inst* 1995;87:1622–1629
24. Boyd NF, Stone J, Martin L, Minkin S, Yaffe M, Sunnybrook and Women's College Hospital, Mammographic densities and the growth hormone-IGF-1 prolactin axis. *Proc 92nd Meeting of the American Association for Cancer Research*, New Orleans, LA, 2001, p 558 (Abstract)
25. Byrne C, Hankinson SE, Colditz GA, Willett WC, Speizer FE, Channing Laboratory, Plasma prolactin and mammographic density in postmenopausal women. *Proc 92nd Meeting of the American Association for Cancer Research*, New Orleans, LA, 2001, p 153 (Abstract)
26. Gray G.E, Pike M.C, Hirayama T, Tellez J, Gerkins V, Brown J.B, Casagrande J.T, Henderson B.E, Diet and hormone profiles in teenage girls in four countries at different risk for breast cancer. *Prev Med* 1982;11:108–113
27. Rossing M.A, Scholes D, Cushing-Haugen K.L, Voigt L.F, Cimetidine use and risk of prostate and breast cancer. *Cancer Epidemiol Biomarkers Prev* 2000; 9:319–323
28. Endogenous Hormones and Breast Cancer Collaborative Group, Endogenous sex hormones and breast cancer in postmenopausal women: collaborative reanalysis of nine prospective studies. *J Natl Cancer Inst*. 2002;94:606–616
29. Strungs I, Gray R.A, Rigby H.B, Strutton G, Two case reports of breast carcinoma associated with prolactinoma. *Pathology* 1997;29: 320–323
30. Volm M.D, Talamonti M.S, Thangavelu M, Gradishar W.K, Pituitary adenoma and bilateral male breast cancer: an unusual association. *J Surg Oncol* 1997;64:74–78